Bioprinting a novel glioblastoma tumor model using a fibrin-based bioink for drug screening
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Abstract Glioblastoma multiforme (GBM), a deadly primary brain cancer, exhibits invasive proliferation into healthy brain tissue. Currently, novel treatment methods are being investigated as possible alternatives to the current standard of care for the disease, which consists of tumor resection followed by additional treatment to prevent tumor recurrence. However, investigation into novel GBM treatments remains hindered by the limited ability of preclinical disease models to accurately assess drug effectiveness and toxicity. Recent developments in the fields of biotechnology and tissue engineering have made 3D bioprinting of hydrogel-based biomaterial scaffolds a feasible method for rapidly producing an accurate in vitro model for glioblastoma, custom designed to the needs of the investigator. Here, we developed a novel fibrin-based 3D printed GBM model for cellular characterization and drug screening using an Aspect Biosystems RX1 bioprinter. Their Lab-On-a-Printer™ microfluidic print head minimizes shear stress, allowing for effective printing of delicate neural tissue. Printed glioblastoma cell–laden structures displayed high levels of cell viability for 12 days following initial printing. Furthermore, printed cells spontaneously formed spheroids with upregulated levels of the proteins CD133 and DCX markers associated with cancer stem cells and metastatic invasiveness, respectively. Printed scaffolds were then treated with a novel chemical treatment method previously tested in 2D culture and showed significant resistance, indicating the 3D printed glioblastoma model's potential as a more accurate representation of the in vivo response to drug treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling Tissue Morphogenesis and Cancer in 3D
Yamada, K. M., & Cukierman, E. (2007) · Cell · doi:10.1016/j.cell.2007.08.006 · Cited by 1,751
Three-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
Zanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., Bevilacqua, A., & Tesei, A. (2016) · Scientific Reports · doi:10.1038/srep19103 · Cited by 1,144
Scalable Stirred-Suspension Bioreactor Culture of Human Pluripotent Stem Cells
Kehoe, D. E., Jing, D., Lock, L. T., & Tzanakakis, E. S. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0454 · Cited by 264
Cited by
Natural Hydrogel-Based Bio-Inks for 3D Bioprinting in Tissue Engineering: A Review
Fatimi, A., Okoro, O. V., Podstawczyk, D., Siminska-Stanny, J., & Shavandi, A. (2022) · Gels · doi:10.3390/gels8030179 · Cited by 276
“However, in general, the extrusion bioprinting approach has been used to fabricate 3D tissues and biological constructs including kidney [89], liver [98], blood vessels [93], tissue-engineered muscle [121], human intestinal tissue [97], adipose tissues [95,96], tracheal graft [37], tooth tissue [122], vascularized sof…”
MethodEmerging Technologies in Multi‐Material Bioprinting
Ravanbakhsh, H., Karamzadeh, V., Bao, G., Mongeau, L., Juncker, D., & Zhang, Y. S. (2021) · Advanced Materials · doi:10.1002/adma.202104730 · Cited by 266
3D Bioprinting of Tumor Models for Cancer Research
Kang, Y., Datta, P., Shanmughapriya, S., & Ozbolat, I. T. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00791 · Cited by 112
Proteinaceous Hydrogels for Bioengineering Advanced 3D Tumor Models
Blanco‐Fernandez, B., Gaspar, V. M., Engel, E., & Mano, J. F. (2021) · Advanced Science · doi:10.1002/advs.202003129 · Cited by 78
Metadata
- Authors
- Lee, C., Abelseth, E., de la Vega, L., & Willerth, S. M.
- Venue
- Materials Today Chemistry
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 12
- Pages
- 78-84
- ISSN
- 2468-5194 (ISSN-L)
- OpenAlex
- W2908955968
- Cited by
- 134
- References
- 4
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.